Ergoteles’s Arbutus Biopharma ABUS Stock Holding History

Ergoteles’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-15,000	Closed	-$45.5K	–	997
2023 Q1	$45.5K	Buy	+15,000	New	+$42.3K	﹤0.01%	1140

Other funds holding ABUS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Ergoteles's ABUS Position: Q2 2023 in Review

Ergoteles sold out of Arbutus Biopharma (ABUS) in Q2 2023, closing a stake of 15,000 shares — an estimated $45.5K sold.

Ergoteles first reported a position in ABUS in Q1 2023 and held it in 1 quarter. The position peaked at $45.5K in Q1 2023. 111 funds tracked by Wall St. Rank hold ABUS as of Q2 2023.

Ergoteles reported no remaining Arbutus Biopharma position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 15,000 Arbutus Biopharma shares in Q2 2023, an estimated $45.5K.
Ergoteles first reported a position in Arbutus Biopharma in Q1 2023 and held it in 1 quarter.
Ergoteles's Arbutus Biopharma position peaked at $45.5K in Q1 2023.
111 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.